Using recombinant DNA technology to produce drugs in simple organisms like bacteria and yeast is nothing new. Animal-derived insulin was phased out in the early 1980s when Eli Lilly offered the first insulin drug created using recombinant techniques. Using an expression vector for the protein and injecting it into mammalian cells allowed for cheaper, more reproducible production of drugs. Other examples include erythropoietin, interferon, and the anti-Her2 monoclonal antibody.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.